Liproca Depot (hydroxyflutamide) News

|||||||||| Liproca Depot (hydroxyflutamide) / Lidds, Jiangxi Puheng Pharma
Clinical, Journal: Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. (Pubmed Central) - Apr 14, 2022
PSA and prostate volume decreased in most patients. Indications of efficacy were shown by post-treatment MRI and biopsies demonstrating stabilization or regression in the majority of cases.

||||||||||  Liproca Depot (hydroxyflutamide) / Lidds, Jiangxi Puheng Pharma
Trial completion:  A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer (clinicaltrials.gov) -  Mar 11, 2016
P2, N=23, Completed,  Sponsor: Lidds AB
Indications of efficacy were shown by post-treatment MRI and biopsies demonstrating stabilization or regression in the majority of cases. Recruiting --> Completed

||||||||||  Liproca Depot (hydroxyflutamide) / Lidds, Jiangxi Puheng Pharma
New P2 trial:  A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer (clinicaltrials.gov) -  Jan 20, 2015
P2, N=28, Recruiting,  Sponsor: Lidds AB

||||||||||  Liproca Depot (hydroxyflutamide) / Lidds, Jiangxi Puheng Pharma
Trial completion, Trial primary completion date:  2-HOF: An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate (clinicaltrials.gov) -  Jan 20, 2015
P1/2, N=24, Completed,  Sponsor: Lidds AB
Recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2010 --> May 2011



	Diseases Companies Products Productz Mechanisms of Action Sites